Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.64 |
| ▸ | ACLY | P53396 | 13/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TPMT | P51580 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SELL | P14151 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
| ▸ | FUT4 | P22083 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30657973 | 1.00 | TTR (0.64) | TTRACLYTSHRTPMTCA1 | |
| SCHEMBL22000624 | 0.85 | TTR (0.44) | TTRACLYCA1CA2 | |
| SCHEMBL9040901 | 0.83 | TTR (0.50) | TTRACLYTSHRTPMTSMN1; SMN2 | |
| SCHEMBL20130408 | 0.81 | HSD17B10 (0.46) | TTRACLYTPMTCA1CA2 | |
| SCHEMBL25171764 | 0.80 | TTR (0.62) | TTRACLYTPMTCA1CA2 | |
| SCHEMBL21931117 | 0.80 | CA12 (0.45) | TTRACLYTPMTCA1CA2 | |
| SCHEMBL30657947 | 0.80 | CA12 (0.45) | TTRACLYTPMTCA1CA2 | |
| SCHEMBL25472101 | 0.80 | TPMT (0.48) | TTRACLYTPMTCA1CA2 | |
| SCHEMBL10934779 | 0.80 | TTR (0.47) | TTRACLYTSHRTPMTSMN1; SMN2 | |
| SCHEMBL29070103 | 0.80 | TTR (0.47) | TTRACLYTSHRTPMTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522280-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250066354-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-12139487-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| WO-2023220219-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220219-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230365560-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365560-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365560-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023078127-A1 | MACROCYCLIC SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 中国药科大学 | 2023-05-11 | — | — | WO | disclosed |
| US-11555012-B2 | ACLY inhibitors and uses thereof | Nimbus Artemis, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2297103-B1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| CN-102112445-A | Hydroxyphenylsulfonamides as antiapoptotic Bcl inhibitors | BRISTOL MYERS SQUIBB CO | 2011-06-29 | — | — | CN | disclosed |
| EP-2297103-A1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009152082-A1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066354-A1 | COMPOUNDS AND USES THEREOF | BRCA1, VHL, TFEB | TTR 2541/4885ACLY 1280/4885TSHR 4165/4885 |
| US-11555012-B2 | ACLY inhibitors and uses thereof | ACLY, ATP5ME, ATP5MG | TTR 4425/4885ACLY 1/4885TSHR 4803/4885 |
| US-12139487-B2 | Compounds and uses thereof | BRCA1, VHL, TFEB | TTR 2541/4885ACLY 1280/4885TSHR 4165/4885 |
| US-20230365560-A1 | COMPOUNDS AND USES THEREOF | BRCA1, VHL, TFEB | TTR 2541/4885ACLY 1280/4885TSHR 4165/4885 |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | TTR 563/4885ACLY 4026/4885TSHR 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.